---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-071153"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:26:42.538637+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics Q3 net loss $11.9M; cash $51M; positive JSP191 data in Fanconi Anemia

## Summary
- Net loss of $11.9M for Q3 2022 vs $3.4M in Q3 2021; R&D expenses $9.0M, G&A $3.7M.
- Cash and equivalents $51.0M as of Sept 30, 2022, expected to fund operations through early 2023.
- Positive clinical data: JSP191 conditioning achieved 100% donor chimerism in first two Fanconi Anemia patients.
- FDA Fast Track designation granted for JSP191 in Severe Combined Immunodeficiency (SCID) transplant.
- Registrational study in AML/MDS and new MDS second-line study expected to start Q1 2023.

## SEC filing metadata
- accession: 0001213900-22-071153
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390022071153/0001213900-22-071153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390022071153/ea168345-8k_jasperthera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-071153
- JSON: https://secwatch.observer/filing/0001213900-22-071153.json
- Plain text: https://secwatch.observer/filing/0001213900-22-071153.txt

## Key facts
- Earnings Releases
  Jasper Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $11.9 million.
  - Period: the quarter ended September 30, 2022
  - Net income: $11.9 million
  - Result: reported results
  source text: Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390022071153/0001213900-22-071153-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.